Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.

Hang-Long LiGregory Y H LipQi FengYue FeiYi-Kei TseMei-Zhen WuQing-Wen RenHung-Fat TseBernard-M Y CheungKai-Hang Yiu

Published in: Cardiovascular diabetology (2021)

SGLT2i reduced the risk of cardiac arrhythmias. Our study provides further evidence for recommending the use of SGLT2i in patients with DM, CKD, and HF. Further research is needed to fully elucidate the mechanism by which SGLT2i protect against arrhythmias.

Keyphrases

congenital heart disease
left ventricular
chronic kidney disease
type diabetes
heart failure
metabolic syndrome
adipose tissue
atrial fibrillation